Drugs / Somavaratan
Somavaratan
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01359488 | Mar 2011 → Jun 2012 | pituitary deficiency | Versartis Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01718041 | Oct 2012 → Jul 2014 | pituitary deficiency | Versartis Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02719990 | Feb 2016 → Jan 2018 | pituitary deficiency | Versartis Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02526420 | Jul 2015 → Oct 2016 | pituitary deficiency | Versartis Inc. | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02413138 | Aug 2015 → Nov 2017 | pituitary deficiency | Versartis Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT02068521 | Mar 2014 → Nov 2017 | pituitary deficiency | Versartis Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT00673309 | Jul 2000 → Apr 2011 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03145831 | Mar → Nov 2017 | pituitary deficiency | Versartis Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02339090 | Aug 2015 → Aug 2017 | — | Versartis Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somavaratan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145831 ↗ |
| Known as | IGFBP-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00673309 ↗ |
| Known as | VRS-317 | “An Open-label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)” NCT02719990 ↗ |
| Modality | Protein / enzyme biologic | “long-acting rhGH analog, VRS-317” PMID 23585663 ↗ Apr 2013 |
| Route | Subcutaneous | “After Subcutaneous Administration of VRS-317” NCT01359488 ↗ |